Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

OvaScience and Millendo Agree to Merge to Focus on Rare Endocrine Disease
Rare Daily Staff Millendo Therapeutics and OvaScience said they will merge in a $60 million stock swap that will create a public, late-stage… Continue Reading
U.S. FDA Grants Fast Track Designation for BioCryst’s HAE Drug
Rare Daily Staff The U.S. Food and Drug Administration granted BioCryst Pharmaceuticals Fast Track designation for BCX7353 for the… Continue Reading
FDA Approves Kyowa Kirin’s Poteligeo for Rare Forms of NHL
Rare Daily Staff The U.S. Food and Drug Administration today approved Kyowa Kirin’s Poteligeo for the treatment of adult patients with… Continue Reading
FDA Expands Approval of Vertex CF Drug Orkambi to Include Kids 2 to 5
Rare Daily Staff The U.S. Food and Drug Administration expanded the approved use Vertex Pharmaceuticals’ Orkambi to include children ages… Continue Reading
It’s Good to Have Friends
It was nearly ten years ago when Charles Alvin Middleton became ill on a flight home to Tampa Bay, Florida from a business trip. He was met… Continue Reading
Acadia Enters License Agreement with Neuren Worth up to $465 Million for Experimental Rett Syndrome Drug
Rare Daily Staff Acadia Pharmaceuticals entered into an exclusive North American license agreement with Neuren Pharmaceuticals for the… Continue Reading
FDA grants Amryt Pediatric Rare Disease Designation for Experimental Drug to Treat Epidermolysis Bullosa
Rare Daily Staff The U.S. Food and Drug Administration granted Amryt Pharma a Rare Pediatric Disease designation for AP101, the company’s… Continue Reading
be-a-guest-blogger

Follow us on Twitter